BR112017024253A2 - métodos de tratamento de inflamação ou dor neuropática. - Google Patents

métodos de tratamento de inflamação ou dor neuropática.

Info

Publication number
BR112017024253A2
BR112017024253A2 BR112017024253A BR112017024253A BR112017024253A2 BR 112017024253 A2 BR112017024253 A2 BR 112017024253A2 BR 112017024253 A BR112017024253 A BR 112017024253A BR 112017024253 A BR112017024253 A BR 112017024253A BR 112017024253 A2 BR112017024253 A2 BR 112017024253A2
Authority
BR
Brazil
Prior art keywords
methods
neuropathic pain
treating inflammation
inflammation
treating
Prior art date
Application number
BR112017024253A
Other languages
English (en)
Portuguese (pt)
Inventor
Wayne Thurston Archie Jr
Rodney Beals Channing
A Grice Cheryl
paul o'neill Gary
peter fraser Iain
Lorayne BLANKMAN Jacqueline
Robert CLAPPER Jason
Alan B Ezekowitz R
K Jones Todd
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of BR112017024253A2 publication Critical patent/BR112017024253A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017024253A 2015-05-11 2016-05-10 métodos de tratamento de inflamação ou dor neuropática. BR112017024253A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159770P 2015-05-11 2015-05-11
US201662297670P 2016-02-19 2016-02-19
PCT/US2016/031668 WO2016183097A1 (en) 2015-05-11 2016-05-10 Methods of treating inflammation or neuropathic pain

Publications (1)

Publication Number Publication Date
BR112017024253A2 true BR112017024253A2 (pt) 2018-07-24

Family

ID=57249499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024253A BR112017024253A2 (pt) 2015-05-11 2016-05-10 métodos de tratamento de inflamação ou dor neuropática.

Country Status (14)

Country Link
US (3) US10450302B2 (https=)
EP (1) EP3294731A4 (https=)
JP (2) JP2018515460A (https=)
KR (1) KR20180004263A (https=)
CN (2) CN113413387A (https=)
AU (3) AU2016262459A1 (https=)
BR (1) BR112017024253A2 (https=)
CA (1) CA2984480A1 (https=)
EA (1) EA201792496A1 (https=)
HK (1) HK1252658A1 (https=)
IL (2) IL255239A0 (https=)
MX (2) MX2017014344A (https=)
SG (1) SG10202012002TA (https=)
WO (1) WO2016183097A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
KR20190085046A (ko) * 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
DK3541807T3 (da) * 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL297470A (en) * 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
US12599600B2 (en) * 2020-05-29 2026-04-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
CN119031909A (zh) * 2022-03-31 2024-11-26 梅约医学教育与研究基金会 用于治疗胰腺疾病和病症的方法和材料
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (https=) 1967-10-17 1970-06-01
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
WO1993011097A1 (en) 1991-11-27 1993-06-10 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO1995017439A2 (en) 1993-12-22 1995-06-29 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
TW200531694A (en) 2004-02-18 2005-10-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
WO2011054795A1 (de) 2009-11-03 2011-05-12 Bayer Materialscience Ag Fluorurethane als additive in einer photopolymer-formulierung
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
EP2828253A1 (en) * 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
LT3470063T (lt) 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
MX2017014344A (es) 2018-04-11
US20200055841A1 (en) 2020-02-20
CN113413387A (zh) 2021-09-21
US10450302B2 (en) 2019-10-22
US11034674B2 (en) 2021-06-15
SG10202012002TA (en) 2021-01-28
JP2022008597A (ja) 2022-01-13
HK1252658A1 (zh) 2019-05-31
AU2020213382A1 (en) 2020-08-27
EP3294731A1 (en) 2018-03-21
JP2018515460A (ja) 2018-06-14
MX2021014815A (es) 2022-01-18
AU2022203543A1 (en) 2022-06-16
AU2016262459A1 (en) 2017-12-21
CN107849021A (zh) 2018-03-27
IL255239A0 (en) 2017-12-31
US20210230145A1 (en) 2021-07-29
EP3294731A4 (en) 2018-10-24
CA2984480A1 (en) 2016-11-17
IL284299A (en) 2021-07-29
WO2016183097A1 (en) 2016-11-17
EA201792496A1 (ru) 2018-04-30
US20180099951A1 (en) 2018-04-12
KR20180004263A (ko) 2018-01-10

Similar Documents

Publication Publication Date Title
BR112017024253A2 (pt) métodos de tratamento de inflamação ou dor neuropática.
IL269371A (en) Treatment methods
PL3265053T3 (pl) Sposoby leczenia skóry
PT3785717T (pt) Métodos para o tratamento de infeções por coronaviridae
PL3288581T3 (pl) Sposób leczenia nowotworu
IL251215B (en) Cannabinoid composition and method for treating pain
BR112017018413A2 (pt) tratamento de pancreatite
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
PT3265087T (pt) Método de tratamento com tradipitant
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
EP3215219C0 (en) SKIN TREATMENT SYSTEM
PL3393468T3 (pl) Metody leczenia niedoboru odporności
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
PT3408417T (pt) Método de tratamento térmico
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
IL257764B (en) Methods for treatment of diseases
IL256111B1 (en) Pac–1 combination therapy
EP3630331C0 (en) FLUID TREATMENT
EP3597225A4 (en) TREATMENT PROCESS
IL254825A0 (en) Methods of treatment with taselisib
PL3661510T3 (pl) Sposoby leczenia zmian zachowania
LT3209319T (lt) Grybelinių infekcijų gydymo būdas
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
IL254155A0 (en) pain treatment
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S (DK)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 403/10 , C07D 213/55 , C07D 295/192 , C07D 295/205 , C07D 403/00

Ipc: C07D 295/205 (2006.01), C07D 213/55 (2006.01), C07

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]